GILD/ABBV/ENTA—This sounds like posturing by the PBMs and third-party payers to induce GILD to set the price of the not-yet-approved Sovaldi + Ledipasvir combination at a small (or zero) premium to Sovaldi itself.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.